• Something wrong with this record ?

Cognitive performance and lifetime cannabis use in patients with first-episode schizophrenia spectrum disorder

M. Hájková, K. Knížková, A. Siroňová, B. Keřková, J. Jonáš, P. Šustová, A. Dorazilová, M. Rodriguez

. 2021 ; 26 (4) : 257-272. [pub] 20210511

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21025430

INTRODUCTION: Cognitive impairment is among the core features of schizophrenia. In a healthy population, the cognitive deficit is often linked with cannabis abuse, and although the same would be expected in patients with schizophrenia, research has presented contradictory results. METHODS: Participants were patients with first-episode schizophrenia (FES) spectrum disorder who had been lifetime cannabis users (N = 30), FES non-users (N = 53) as well as healthy controls (HC) also divided into cannabis users (N = 20) and non-users (N = 49). All participants underwent an extensive neurocognitive assessment and filled in a cannabis questionnaire, which allowed for a comparison of the four groups on cognitive functioning. RESULTS: FES patients using cannabis showed less impaired cognitive functioning with the most prominent difference in visual memory compared to FES non-users. However, they differed neither in the clinical assessment of general psychopathology, positive and negative symptoms, nor in medication from the patient's non-users. A comparison of the HC who used cannabis, and those who did not, revealed no sizeable differences in cognitive performance between the groups. CONCLUSIONS: The results delivered supporting evidence for the trend of superior neurocognitive performance in FES patients with a lifetime history of cannabis use compared to non-using patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025430
003      
CZ-PrNML
005      
20211026133825.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/13546805.2021.1924649 $2 doi
035    __
$a (PubMed)33973827
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Hájková, M $u Institut of Neuropsychiatric Care, Prague, Czech Republic $u Military University Hospital Prague, Prague, Czech Republic
245    10
$a Cognitive performance and lifetime cannabis use in patients with first-episode schizophrenia spectrum disorder / $c M. Hájková, K. Knížková, A. Siroňová, B. Keřková, J. Jonáš, P. Šustová, A. Dorazilová, M. Rodriguez
520    9_
$a INTRODUCTION: Cognitive impairment is among the core features of schizophrenia. In a healthy population, the cognitive deficit is often linked with cannabis abuse, and although the same would be expected in patients with schizophrenia, research has presented contradictory results. METHODS: Participants were patients with first-episode schizophrenia (FES) spectrum disorder who had been lifetime cannabis users (N = 30), FES non-users (N = 53) as well as healthy controls (HC) also divided into cannabis users (N = 20) and non-users (N = 49). All participants underwent an extensive neurocognitive assessment and filled in a cannabis questionnaire, which allowed for a comparison of the four groups on cognitive functioning. RESULTS: FES patients using cannabis showed less impaired cognitive functioning with the most prominent difference in visual memory compared to FES non-users. However, they differed neither in the clinical assessment of general psychopathology, positive and negative symptoms, nor in medication from the patient's non-users. A comparison of the HC who used cannabis, and those who did not, revealed no sizeable differences in cognitive performance between the groups. CONCLUSIONS: The results delivered supporting evidence for the trend of superior neurocognitive performance in FES patients with a lifetime history of cannabis use compared to non-using patients.
650    12
$a Cannabis $x škodlivé účinky $7 D002188
650    _2
$a kognice $7 D003071
650    12
$a kognitivní poruchy $7 D003072
650    _2
$a lidé $7 D006801
650    12
$a abúzus marihuany $7 D002189
650    12
$a schizofrenie $7 D012559
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Knížková, K $u National Institute of Mental Health, Klecany, Czech Republic $u Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Siroňová, A $u National Institute of Mental Health, Klecany, Czech Republic $u Department of Psychology, Faculty of Social Studies, Masaryk University, Brno, Czech Republic
700    1_
$a Keřková, B $u National Institute of Mental Health, Klecany, Czech Republic
700    1_
$a Jonáš, J $u National Institute of Mental Health, Klecany, Czech Republic $u Department of Psychology, Faculty of Arts, Charles University in Prague, Prague, Czech Republic
700    1_
$a Šustová, P $u National Institute of Mental Health, Klecany, Czech Republic $u Department of Psychology, Faculty of Arts, Charles University in Prague, Prague, Czech Republic
700    1_
$a Dorazilová, A $u National Institute of Mental Health, Klecany, Czech Republic
700    1_
$a Rodriguez, M $u National Institute of Mental Health, Klecany, Czech Republic $u Department of Psychology, Faculty of Arts, Charles University in Prague, Prague, Czech Republic
773    0_
$w MED00006297 $t Cognitive neuropsychiatry $x 1464-0619 $g Roč. 26, č. 4 (2021), s. 257-272
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33973827 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133831 $b ABA008
999    __
$a ok $b bmc $g 1714467 $s 1145937
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 26 $c 4 $d 257-272 $e 20210511 $i 1464-0619 $m Cognitive neuropsychiatry $n Cognit Neuropsychiatry $x MED00006297
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options